Pharma BD Deal Intelligence

Biocon Biologics Ltd. / Viatris Biosimilars Business

2022 · Asset Purchase · $3.0B · Complete

Announcement Sentiment

67

Positive

Outcome Score

72

Largely worked — most objectives met.

Biocon Biologics acquired Viatris biosimilars business for $3B.

Key facts

Announced Feb 28, 2022
Closed Nov 29, 2022
Deal value $3.0B
Deal type Asset Purchase

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals